enVVeno Medical Corp (NVNO) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$8.95

From 52W high−74.63%

Volume6741.00

Market cap$6.10M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$8.95

From 52W high

−74.63%

Volume

6741.00

Market cap

$6.10M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.0x

P/E (TTM)

—

RSI (14)

34.2

MomentumView details →

1D Return

−0.15%

YTD Return

−21.58%

SummaryUpdated Jun 1, 2026

enVVeno Medical Corporation (NASDAQ:NVNO) is a medical device company founded in 1999 and based in Irvine, California. Originally incorporated as Hancock Jaffe Laboratories, Inc., the company rebranded to enVVeno Medical Corporation in October 2021 to better reflect its focus on venous disease treatment solutions. The company went public in May 2018 and specializes in developing bioprosthetic tissue-based medical devices designed to improve treatment standards for patients suffering from venous diseases.

Ask drillr about enVVeno Medical Corp →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

1.0x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−76.07%

ROA (TTM)

−69.39%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+64.91%

FCF YoY

+14.65%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+97.87%

EBITDA YoY

+30.97%

MomentumView details →

1D Return

−0.15%

YTD Return

−21.58%

1Y Return

−73.04%

RSI (14)

34.2

vs 50D SMA

−15.97%

vs 200D SMA

−18.41%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

11.70x

Quick Ratio

11.70x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$5.37

EPS Surprise

−14.50%

Beats (12Q)

7/12

Next Q EPS Est

−$3.27

Avg Surprise (4Q)

7.77%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−15.72M

Op. CF (TTM)

−14.62M

Next earningsOct 30, 2026 →

Latest newsMore news →

ENVVENO MEDICAL CORP filed a mixed shelf registration statement to offer up to $100 million in securities.30d ago

enVVeno Medical highlighted the publication of a peer-reviewed health economic study in the Journal of Vascular Surgery: Venous and Lymphatic Disorders demonstrating the cost-effectiveness of its enVVe replacement venous valve therapy versus standard of care for deep venous chronic venous insufficiency.47d ago

Similar companies

20/20 Biolabs, Inc. Common StockAIDX IceCure Medical LtdICCM Bone Biologics CorporationBBLGW Autonomix Medical, Inc. Common StockAMIX Pheton Holdings Ltd Class A Ordinary SharesPTHL Bluejay Diagnostics, Inc.BJDX Find similar companies →

Latest newsMore news →

ENVVENO MEDICAL CORP filed a mixed shelf registration statement to offer up to $100 million in securities.30d ago enVVeno Medical highlighted the publication of a peer-reviewed health economic study in the Journal of Vascular Surgery: Venous and Lymphatic Disorders demonstrating the cost-effectiveness of its enVVe replacement venous valve therapy versus standard of care for deep venous chronic venous insufficiency.47d ago enVVeno Medical received FDA IDE approval to begin the TAVVE pivotal trial for its enVVe System, a first-in-class minimally invasive replacement venous valve.51d ago